Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149

Resistance to platinum-based chemotherapy becomes a major obstacle in non-small-cell lung cancer (NSCLC) treatment. Overexpression of the excision repair cross-complementing 1 (ERCC1) gene is reported to negatively influence the effectiveness of cisplatin-based therapy for NSCLC cells. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yuwen, Chen, Danyang, Yi, Yanmei, Zeng, Shanshan, Liu, Shuang, Li, Pan, Xie, Hui, Yu, Pengjiu, Jiang, Guanmin, Liu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251316/
https://www.ncbi.nlm.nih.gov/pubmed/32478168
http://dx.doi.org/10.1016/j.omto.2020.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251316/
https://www.ncbi.nlm.nih.gov/pubmed/32478168
http://dx.doi.org/10.1016/j.omto.2020.05.001

Ejemplares similares